PBPK Modeling: Empowering Drug Development and Precision Dosing in China
CPT: Pharmacometrics & Systems Pharmacology · 2025-05 · 14 (5) · 828-839
DOI: 10.1002/psp4.70004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 18.02.2025. Verfasst von Dongsheng Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Drug Development, Models, Biological, Pharmacokinetics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
- Quzhou Fudan Institute, Quzhou, China.
- National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Shanghai, China.
ORCID-Profile: Dongsheng Yang, Jian Li, Wen Yao Mak, Aole Zheng, Xiao Zhu, Qingfeng He, Xiaoqiang Xiang
Zitieren
APA
Yang, D., Li, J., Mak, W. Y., Zheng, A., Zhu, X., He, Q., Wang, Y., & Xiang, X. (2025). PBPK Modeling: Empowering Drug Development and Precision Dosing in China. CPT: Pharmacometrics & Systems Pharmacology, 14(5), 828-839. https://doi.org/10.1002/psp4.70004
Vancouver
Yang D, Li J, Mak WY, Zheng A, Zhu X, He Q, et al. PBPK Modeling: Empowering Drug Development and Precision Dosing in China. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(5):828-839. doi:10.1002/psp4.70004
BibTeX
@article{Yang2025,
author = {Yang, Dongsheng and Li, Jian and Mak, Wen Yao and Zheng, Aole and Zhu, Xiao and He, Qingfeng and Wang, Yuzhu and Xiang, Xiaoqiang},
title = {PBPK Modeling: Empowering Drug Development and Precision Dosing in China},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {5},
pages = {828--839},
doi = {10.1002/psp4.70004}
}
EUVIMED